| References | Intervention | Subjects | (m/f) | Age (years) | FN BMD (g/cm2) | Fx prevalence (%) | BMSi | Relationship of BMSi with | Study quality scale (0–10) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | BMD | Intervention | |||||||||
| LONGITUDINAL DESIGN | |||||||||||
| Guerri-Fernandez et al. (52) | ART with TDF/FTC, FU 24 (not shown) + 48 weeks | HIV | 40 (33/7) | 38 ± 9 |
BL: 0.84 ± 0.12 FU: 0.81 ± 0.11 |
5.0 |
BL: 86.1 ± 6.1 (84.2–88.0) FU: 89.0 ± 4.2 (87.7–90.3) |
Neg | Pos | Increase with ART | 7 |
| Lerma-Chippirraz et al. (59) | ART with TDF/FTC, FU 48 weeks (HIV only) | HIV | 20 (16/4) | 37 [31–43] | BL: 0.84 [0.79–1.02]FU: 0.82 [0.73–0.96] | 0 | BL: 86 [83–90]FU: 90 [88–93] | NA | NA | Increase with ART | 4 |
| Controls | 20 (15/5) | 38 [35–42] | BL: 0.83 [0.75–0.98] | 0 | BL: 89 [88–93] | ||||||
| Perez-Saez et al. (53) | Low-dose GC after KT, FU 3 (not shown) + 12 months | ESRD receiving KT | 36 (19/17) | 54.9 ± 11.6 |
BL: 0.75 ± 0.15 FU: 0.73 ± 0.14 |
16.7 |
BL: 79.2* [73.2–85.4] FU: 80.1* [73.0–85.4] |
NA | NA | No | 6 |
Age is presented as mean ± SD (range, if reported), mean (SE) or median [IQR], BMD is presented as mean ± SD, mean (95% CI), median [IQR] or median (SE) and BMSi is presented as mean ± SD (95% CI), mean (SE) (95% CI) or median [IQR]. 95% CI calculated from data provided in the publication. Ab, published only in Abstract form; ABC/3TC, Abacavir/lamivudine; ART, Antiretroviral therapy; BL, Baseline; BMD, Bone mineral density; BMSi, Bone material strength index; CAG, Chronic atrophic gastritis; ESRD, End-stage renal disease; FN, Femoral neck; FU, Follow-up; Fx, Fracture; IFG, Impaired fasting glucose; HypoPT, Hypoparathyroidism; MGUS, Monoclonal gammopathy of undetermined significance; PHPT, Primary hyperparathyroidism; DM, Diabetes mellitus; TDF/FTC, Tenofovir/emtricitabine. *Measured in a subgroup of subjects.